Journal of Advanced Zoology

ISSN: 0253-7214

Volume 45 Issue 01 Year 2024 Page 529:536

Understanding and Treating Acute Lung Injury: Exploring The Causes, How It Affects The Lungs, and Possible Medications

Piyushkumar Sadhu [a*], Falguni Rathod [b,c], Mamta Kumari [a], Niyati Shah [a], Chitrali Talele [a], Hemraj Singh Rajput [a], Nirmal Shah [a]

[a] *Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat – 391760, India.*

[b] *Sumandeep Nursing College, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat – 391760, India.*

[c] *Faculty of Nursing, Noble University, Junagadh, Gujarat – 360 001, India.*

***Corresponding author:** Piyushkumar Sadhu*

**Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India.; Email I'd - piyush.dop@sumandeepvidyapeethdu.edu.in; ORCID I'd:0000-0001-5725-1861*

Article History

Received: 03/12/2023
Revised: 22/12/2023
Accepted: 05/01/2024

Abstract

Acute lung injury is a life-threatening condition characterized by hypoxemia, pulmonary edema, and inflammation. This comprehensive review delves into the intricate landscape of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS), shedding light on the multifaceted challenges and advancements in their understanding and treatment. The exploration of pathological features, pharmacological interventions, and long-term outcomes unveils the complexities inherent in managing these critical respiratory conditions. The etiology of ALI/ARDS is diverse and includes direct and indirect insults to the lungs. Key findings underscore the hurdles posed by the heterogeneous patient population, emphasizing the imperative of tailoring interventions based on individual characteristics. Ambiguities surrounding optimal timing, dosing, and duration of pharmacological interventions highlight the need for standardized protocols to ensure consistency in treatment approaches. While advancements in mechanical ventilation, fluid management, and pharmacological agents show promise, the absence of reliable biomarkers for treatment response prediction remains a significant limitation. Recommendations for clinical practice encompass personalized and targeted approaches, leveraging technological advancements for individualized care, and advocating for standardized protocols. The pharmacology of ALI/ARDS is complex and challenging, as no specific drug has been proven to be effective in treating ALI. However, several pharmacological agents have been tested or are under investigation for modulating the inflammatory response, reducing oxidative stress, enhancing alveolar fluid clearance, and preventing fibrosis. On a policy level, there is a call for increased research initiatives, specifically in biomarker identification and large-scale trials for emerging treatments. Acknowledging limitations in the evolving nature of research and study heterogeneity, this review stands as a timely and informative resource, providing valuable insights for healthcare practitioners and policymakers navigating the intricate landscape of ALI and ARDS. Implementing the outlined recommendations holds the potential to enhance patient care and guide future research endeavors in this critical field.

Keywords: *Acute lung injury, acute respiratory distress syndrome, etiology, lung injury, smoking*

1. Introduction

Acute Lung Injury (ALI) is a medical condition characterized by sudden and severe damage to the lungs, leading to impaired function and difficulty in breathing. This condition often results from various underlying causes, such as infections, trauma, or inhalation of harmful substances. The hallmark of ALI is the rapid onset of respiratory distress, which can range from mild to severe [1]. Manifesting with rapid onset respiratory distress ranging from mild to severe, diagnosis involves assessing clinical, radiological, and physiological criteria according to the widely used Berlin Definition. Criteria include the timing of symptom onset, chest imaging revealing unexplained opacities, absence of heart failure or fluid overload, and classification of oxygenation impairment severity. A parallel evaluation for exclusion of cardiogenic causes ensures comprehensive diagnostic confirmation, guiding interventions and determining severity [2]. Acute respiratory distress syndrome (ARDS) represents a more severe form of lung injury than ALI and is often considered an advanced stage of the disease (Figure 1). The primary characteristic of ARDS is widespread inflammation in the lungs leading to increased permeability of the alveolar-capillary membrane, causing leakage of fluid into the lungs and impaired oxygen exchange [3]. ARDS diagnosis follows similar principles to ALI, utilizing the Berlin Definition's standardized criteria. A timely and accurate diagnosis of ARDS is essential for implementing effective management, including mechanical ventilation and addressing underlying causes, to improve outcomes for patients facing these challenging respiratory conditions. Table 1 showed the detailed clinical criteria for diagnosis of ALI and ARDS.

Table 1: Clinical Criteria for Diagnosing ALI [2].

Criteria	Definition		Ref.(s)
	ALI	ARDS	
Timing of Onset	Symptoms develop within one week of a known clinical insult or new or worsening respiratory symptoms.	symptoms should develop within one week of a known clinical insult	[3]
Chest Imaging	Bilateral opacities on chest X-ray or CT scan not fully explained by other conditions.	Bilateral opacities on chest X-ray or CT scan, consistent with pulmonary edema, which cannot be fully explained by other conditions	[3,4]
Origin of Edema	Respiratory failure not fully explained by heart failure or fluid overload.	the respiratory failure should not be primarily caused by heart failure or fluid overload.	[5,6]
Oxygenation Impairment as per PaO_2/FiO_2 ratio:			[2,6,7]
Mild	300 to 201	300 and 201	
Moderate	200 to 101	200 and 101	
Severe	100 or less	100 or less	
Exclusion of Cardiogenic Causes	The respiratory failure should not be primarily caused by heart failure or fluid overload.	Cardiogenic causes of respiratory failure should be ruled out	[6,7]

ALI, Acute lung injury; ARDS, Acute respiratory distress syndrome; PaO_2, Partial Pressure of Oxygen; FiO_2, Fraction of Inspired Oxygen

1.1 Partial Pressure of Oxygen (PaO_2)

PaO_2, or partial pressure of oxygen, is a measure of the pressure exerted by oxygen molecules dissolved in arterial blood. It is a critical parameter used to assess the oxygenation status of an individual. Measured in millimeters of mercury (mmHg), PaO_2 reflects the amount of oxygen that has diffused from the lungs into the arterial blood, where it can be transported to the body's tissues. In the context of respiratory conditions like ALI and ARDS, PaO_2 is often used to evaluate the efficiency of oxygen exchange in the lungs. A decrease in PaO_2 may indicate impaired gas exchange, which is a hallmark feature of these respiratory disorders [5,6].

1.2 Fraction of Inspired Oxygen (FiO_2)

FiO_2, or fraction of inspired oxygen, represents the concentration of oxygen in the air that a person inhales. It is expressed as a fraction or percentage and reflects the proportion of oxygen in the total gas mixture being breathed in. In medical settings, FiO_2 is adjusted to meet the patient's oxygenation needs. For individuals with respiratory distress or failure, supplemental oxygen may be administered to increase the FiO_2 and enhance oxygen delivery to the lungs. This is commonly done through devices such as nasal cannulas, masks, or

ventilators. Monitoring and adjusting FiO_2 levels are crucial to maintaining adequate oxygenation in patients with respiratory conditions [7,8].

1.3 PaO_2/FiO_2 Ratio:

The ratio of PaO_2 to FiO_2, often abbreviated as the PaO_2/FiO_2 ratio, is a key parameter used in the assessment and classification of respiratory disorders, particularly ALI and ARDS. This ratio helps categorize the severity of oxygenation impairment [9-11].

$$\text{PaO2} \div \text{FiO2} = \frac{\text{Partial Pressure of Oxygen (PaO2)}}{\text{Fraction of Inspired Oxygen (FiO2)}}$$

The severity classifications for both ALI and ARDS based on the PaO2/FiO2 ratio are as follows:
Mild: PaO_2/FiO_2 between 300 and 201
Moderate: PaO_2/FiO_2 between 200 and 101
Severe: PaO_2/FiO_2 of 100 or less

These classifications assist healthcare professionals in understanding the degree of respiratory impairment and guide appropriate interventions for patients with these conditions.

2. Overview of Epidemiology, Etiology, and Mortality of ALI/ARDS

ALI and its severe form, ARDS, continue to be significant contributors to morbidity and mortality in critically ill patients. Epidemiologically, these conditions affect a diverse population, with a reported incidence ranging from 13.5 to 58.7 cases per 100,000 person-years globally. The prevalence appears to increase with age, and certain comorbidities, such as sepsis and pneumonia, are identified as common precipitating factors [13].

The etiology of ALI/ARDS is multifactorial, involving direct lung injury from conditions like pneumonia, aspiration, or trauma, as well as indirect lung injury from sepsis, pancreatitis, or multiple transfusions. Advances in understanding the molecular and genetic aspects of these conditions have shed light on the intricate pathways leading to lung inflammation and injury (Figure 2). Despite advancements in supportive care and lung-protective ventilation strategies, mortality rates remain substantial. The mortality of ARDS is notably associated with the severity of hypoxemia, with higher mortality rates observed in patients with more severe impairment in oxygenation. The implementation of low tidal volume ventilation and prone positioning has demonstrated improvements in outcomes, yet the overall mortality rates for ARDS persist at around 30-40%, underscoring the ongoing challenges in managing these complex respiratory disorders [14-16].

3. Pathological and Physiological Consequences of ALI/ARDS

Acute Lung Injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are characterized by distinct pathological features that contribute to the impairment of respiratory function. Alveolar edema is a hallmark, involving the accumulation of fluid in the air sacs, leading to reduced oxygen exchange. Hyaline membranes form as a consequence of injury to the alveolar-capillary barrier, resulting in the deposition of proteinaceous material that further hinders gas exchange. Additionally, inflammatory responses may lead to the infiltration of immune cells, causing tissue damage and initiating fibrotic changes. These pathological alterations collectively contribute to the compromised lung structure and function observed in ALI/ARDS. ALI/ARDS induces a cascade of physiological consequences that severely impact respiratory function. Hypoxemia, marked by low levels of oxygen in the arterial blood, is a primary consequence resulting from impaired gas exchange. The disruption of the alveolar-capillary membrane in ALI/ARDS leads to the shunting of blood away from well-ventilated areas, contributing to ventilation-perfusion mismatch and further exacerbating hypoxemia. Impaired gas exchange, in turn, results in respiratory failure, where the lungs fail to provide sufficient oxygen to meet the body's metabolic demands [17]. The physiological consequences extend beyond the respiratory system, affecting various organs and systems due to systemic inflammation and hypoxia. Understanding these pathological features and physiological consequences is crucial for effective management and intervention strategies in the clinical care of ALI/ARDS patients [18].

4. Current Supportive Therapies for ALI/ARDS

Current management strategies for ALI and ARDS involve a multifaceted approach aimed at addressing the complex pathophysiology of these conditions. Several supportive therapies play a pivotal role in improving patient outcomes [19-22].

4.1 Mechanical Ventilation

Mechanical ventilation remains a cornerstone in the management of ALI/ARDS, with a focus on lung-protective ventilation strategies. Low tidal volume ventilation, typically 6 ml/kg of predicted body weight, and plateau pressure limitation help prevent ventilator-induced lung injury. Additionally, positive end-expiratory pressure (PEEP) is employed to maintain alveolar recruitment and improve oxygenation.

4.2 Fluid Management

Optimal fluid management is crucial in preventing fluid overload, which can exacerbate lung injury. Conservative fluid strategies, involving a judicious approach to fluid administration, have been associated with improved outcomes. The emphasis is on avoiding excessive fluid resuscitation, as this can contribute to pulmonary edema and compromise gas exchange.

4.3 Prone Positioning

Prone positioning is utilized as a supportive therapy to enhance oxygenation in patients with severe hypoxemia. Placing patients in the prone position helps achieve a more homogenous distribution of ventilation, thereby improving oxygenation. Prone positioning is often implemented in conjunction with lung-protective ventilation strategies to maximize its benefits.



Figure 1. Illustration of healthy lung (left) and injured lung (right). In ARDS/ALI, injury to the delicate alveolar structure initiates from direct or indirect insults, activating resident alveolar macrophages and promoting the release of pro-inflammatory mediators, chemokines, and the accumulation of neutrophils and monocytes. Reused from Pourfathi et al. 2020. [12].



Figure 2. Etiologies, symptoms, and outcomes of ARDS/ALI. Reused from Pourfathi et al. 2020. [12].

4.4 Extracorporeal Membrane Oxygenation (ECMO)

In refractory cases, extracorporeal membrane oxygenation (ECMO) may be considered as a supportive measure. ECMO provides temporary cardiopulmonary support, allowing for the rest and potential recovery of the lungs. This intervention is typically reserved for severe cases not responsive to conventional therapies.

Recent literature emphasizes the importance of personalized and targeted approaches in the management of ALI/ARDS, taking into account individual patient characteristics and response to specific interventions. Ongoing research continues to refine and advance supportive therapies, with a focus on improving patient outcomes and reducing the overall burden of these critical respiratory conditions.

5. Complications and Long-term Outcomes of ALI/ARDS

ALI and ARDS are associated with a spectrum of complications and long-term outcomes that extend beyond the acute phase of the illness. A comprehensive understanding of these consequences is crucial for providing optimal care and improving overall patient outcomes [23,24].

5.1 Ventilator-Associated Pneumonia (VAP)

Ventilator-associated pneumonia is a frequent complication in ALI/ARDS patients receiving mechanical ventilation. Prolonged ventilator support, impaired cough reflex, and the introduction of invasive devices contribute to an increased risk of bacterial colonization. VAP not only extends the duration of mechanical ventilation but also poses a significant challenge in the management of ALI/ARDS, warranting vigilant infection control measures.

5.2 Pulmonary Hypertension

Pulmonary hypertension can develop as a consequence of chronic hypoxia and vascular remodeling in ALI/ARDS survivors. The persistent elevation of pressure in the pulmonary arteries may lead to right heart strain and eventual right heart failure. Monitoring for signs of pulmonary hypertension and implementing appropriate interventions are essential components of the long-term care of ALI/ARDS survivors.

5.3 Cognitive Impairment

Growing evidence suggests that ALI/ARDS survivors may experience cognitive impairment and neuropsychiatric sequelae, often referred to as post-intensive care syndrome. Cognitive deficits, including memory loss, attention difficulties, and executive dysfunction, can persist long after the resolution of the acute respiratory phase. Comprehensive neuropsychological assessments and supportive interventions are necessary to address these long-term cognitive consequences.

5.4 Muscle Weakness and Debilitation

Prolonged immobilization and muscle disuse during the acute phase of ALI/ARDS contribute to the development of muscle weakness and debilitation. This can result in a significant impact on physical function,

quality of life, and the ability to perform activities of daily living. Early rehabilitation strategies, including physical therapy, are essential in mitigating muscle weakness and facilitating the recovery process.

6. Evaluation of Pharmacological Interventions for ALI/ARDS

The management of ALI/ARDS involves various pharmacological interventions aimed at mitigating inflammation, oxidative stress, and improving overall outcomes. Several agents have been studied, with varying levels of evidence supporting their efficacy.

6.1 Corticosteroids

Corticosteroids have been a subject of debate in the treatment of ALI/ARDS. Some studies suggest potential benefits, such as reduced inflammation and improved oxygenation. However, controversies persist regarding the optimal dose, duration, and timing of corticosteroid administration. Recent research, including the DEXA-ARDS trial, indicates that prolonged use of dexamethasone may improve ventilator-free days but does not significantly impact mortality [25].

6.2 Antioxidants

Antioxidants, including vitamins C and E, have been investigated for their potential to mitigate oxidative stress in ALI/ARDS. While preclinical studies showed promise, clinical trials have yielded mixed results. The absence of consistent evidence has led to uncertainty regarding the routine use of antioxidants in these conditions [26].

6.3 Anti-Inflammatory Agents

Various anti-inflammatory agents, such as statins and monoclonal antibodies targeting specific inflammatory pathways, have been explored. Statins, commonly used for their lipid-lowering properties, have demonstrated anti-inflammatory effects and potential benefits in reducing mortality in ARDS. However, further research is needed to establish their role as standard therapy [27].

7. Identifying Challenges and Gaps in ALI/ARDS Treatment

Despite notable progress in the treatment of ALI/ARDS, several challenges persist. The heterogeneity within the patient population poses a significant hurdle, as ALI/ARDS manifests across a diverse group, complicating the development of universally effective therapies. Tailoring interventions to individual patient characteristics becomes paramount in overcoming this diversity. Additionally, uncertainties surround the optimal timing, dosing, and duration of pharmacological interventions, hindering the establishment of standardized protocols. The lack of reliable biomarkers further adds to the complexity, impeding the ability to predict individual responses to specific therapies. Addressing these challenges is essential for enhancing treatment efficacy and establishing more personalized and targeted approaches for ALI/ARDS patients [28-30].

8. Future directions and conclusion

To address these challenges and gaps, future research should focus on, Precision Medicine Approaches: Embracing precision medicine to tailor interventions based on individual patient profiles, including genetic and biomarker assessments; Exploring Novel Therapies: Investigating novel pharmacological agents targeting specific pathways implicated in ALI/ARDS pathophysiology, with a particular emphasis on anti-inflammatory and anti-fibrotic agents; Leveraging Advances in Technology: Utilizing advancements in technology, such as artificial intelligence and big data analytics, to analyze large datasets and identify patterns that may guide personalized treatment strategies.

This review provides a comprehensive examination of the current state of understanding and treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The exploration of pathological features, pharmacological interventions, and long-term outcomes reveals the complexity of these conditions. The main findings underscore the challenges of managing the heterogeneity within the patient population, the need for precise timing and dosing of pharmacological interventions, and the absence of reliable biomarkers for predicting treatment responses. Despite these challenges, the review highlights ongoing advancements in mechanical ventilation strategies, fluid management, and the exploration of pharmacological agents such as corticosteroids and antioxidants. Recommendations for clinical practice include adopting personalized and targeted approaches, leveraging technological advances for individualized care, and promoting standardized

protocols for pharmacological interventions. In terms of policy, fostering research initiatives to identify biomarkers and conducting large-scale trials for emerging treatments is crucial. Acknowledging the limitations of the review, such as the evolving nature of research and the inherent heterogeneity in study designs, reinforces the need for continual updates and refinements in clinical guidelines. The strengths lie in the synthesis of recent evidence, offering a timely and informative resource for healthcare practitioners and policymakers navigating the complexities of ALI and ARDS management. As the medical community strives for improved outcomes, addressing these recommendations can contribute to enhanced patient care and the advancement of future research in this critical field.

References

1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824. doi:10.1164/ajrccm.149.3.7509706.
2. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669.
3. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-1349. doi:10.1056/NEJM200005043421806.
4. Suter PM, Fairley B, Isenberg MD. Optimal therapeutic level of end-expiratory pressure in acute respiratory distress syndrome. N Engl J Med. 1984;311(5):281-286. doi:10.1056/NEJM198408023110503.
5. Villar J, Pérez-Méndez L, López J, et al. An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2007;176(8):795-804. doi:10.1164/rccm.200610-1534OC.
6. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184(5):561-568. doi:10.1164/rccm.201104-0667OC.
7. Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287(3):345-355. doi:10.1001/jama.287.3.345.
8. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351(4):327-336. doi:10.1056/NEJMoa032193.
9. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575. doi:10.1056/NEJMoa062200.
10. Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. doi:10.1056/NEJM200005043421801.
11. Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012;307(8):795-803. doi:10.1001/jama.2012.120.
12. Pourfathi M, Kadlecek SJ, Chatterjee S, Rizi RR. Metabolic imaging and biological assessment: platforms to evaluate acute lung injury and inflammation. Frontiers in physiology. 2020 Aug 31;11:937.
13. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788-800. doi:10.1001/jama.2016.0291.
14. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562-572. doi:10.1056/NEJMra1608077.
15. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293-1304. doi:10.1056/NEJMoa1011802.
16. Calfee CS, Matthay MA, Eisner MD, Benowitz N, Call M, Pittet JF, Cohen MJ. Active and passive cigarette smoking and acute lung injury after severe blunt trauma. Am J Respir Crit Care Med. 2011 Feb 1;183(3): 318-26. doi: 10.1164/rccm.201004-0630OC.
17. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147-163. doi:10.1146/annurev-pathol-011110-130158.

18. Herridge MS. Fifty years of research in ARDS. Long-term follow-up after acute respiratory distress syndrome. Insights for managing medical complexity after critical illness. American journal of respiratory and critical care medicine. 2017 Dec 1;196(11):1380-4.
19. Pourfathi M. Metabolic Imaging of Acute Lung Injury Using Hyperpolarzied 13 C Magnetic Resonance Imaging. University of Pennsylvania; 2019.
20. Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263. doi:10.1164/rccm.201703-0548ST.
21. Beitler JR, Malhotra A, Thompson BT. Ventilator-Induced Lung Injury. Clin Chest Med. 2016;37(4):633-646. doi:10.1016/j.ccm.2016.06.013.
22. Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69. doi:10.1186/s13613-019-0540-9.
23. Parker AM, Sricharoenchai T, Raparla S, Schneck KW, Bienvenu OJ, Needham DM. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. Crit Care Med. 2015;43(5):1121-1129. doi:10.1097/CCM.0000000000000882.
24. Schmidt M, Demoule A, Polito A, et al. Dyspnea in mechanically ventilated critically ill patients. Crit Care Med. 2011;39(9):2059-2065. doi:10.1097/CCM.0b013e31821b829b.
25. Liu C, Xiao K, Xie L. Advances in the use of exosomes for the treatment of ALI/ARDS. Front Immunol. 2022 Aug 9;13:971189.
26. Jia Q, Yang Y, Chen X, Yao S, Hu Z. Emerging roles of mechanosensitive ion channels in acute lung injury/acute respiratory distress syndrome. Respir Res. 2022 Dec;23(1):1-5.
27. Chacko B, Peter JV, Tharyan P, John G, Jeyaseelan L. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2015(1).
28. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5.
29. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370(23):2191-2200. doi:10.1056/NEJMoa1401520.
30. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331-338. doi:10.1164/rccm.201605-0966OC.